Le Lézard
Classified in: Covid-19 virus
Subject: ATY

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Stride, Inc. - LRN


NEW YORK, Nov. 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Stride, Inc. ("Stride" or the "Company") (NYSE: LRN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Stride and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action] 

On October 16, 2024, Fuzzy Panda Research ("Fuzzy Panda") published a report alleging that Stride has been inflating its earnings by misleading investors about the impact of federal COVID-19 relief funds.  The Fuzzy Panda report claims that more than 25% of Stride's EBITDA came from Elementary and Secondary School Emergency Relief (ESSER) funds, which expired in September 2024.  The report also accuses Stride of hiding "ghost students" and failing to disclose schools leaving the company, alongside allegations of overbilling and fraudulent reimbursement claims. 

On this news, Stride's stock price fell $6.55 per share, or 9.28%, to close at $64.04 per share on October 16, 2024.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP


These press releases may also interest you

at 02:00
SHELL PLC THIRD QUARTER 2024 EURO AND GBP EQUIVALENT DIVIDEND PAYMENTS December 9, 2024 The Board of Shell plc today announced the pounds sterling and euro equivalent dividend payments in respect of the third quarter 2024 interim dividend, which...

at 00:01
As the generative AI map takes shape, the US and China are asserting their dominance. Tech companies from these GenAI superpowers have built a substantial lead in the creation and large-scale commercialization of top-performing large language models...

8 déc 2024
The restored Notre-Dame de Paris cathedral reopened on Sunday, following a grand ceremony held the day before. In his speech at the ceremony, French President Emmanuel Macron expressed gratitude on behalf of the French people to "all those who saved,...

8 déc 2024
Kite, a Gilead Company , today announced findings from three new analyses for Yescarta® (axicabtagene ciloleucel) that demonstrate improved outcomes for people living with relapsed or refractory (R/R) large B-cell lymphoma (LBCL), which were...

8 déc 2024
Genmab A/S : Preliminary analyses from the EPCORE® CLL-1 trial demonstrates overall response rate (ORR) of 61 percent and complete response (CR) rate of 39 percent in heavily pretreated patients with relapsed or refractory (R/R) chronic...

8 déc 2024
Positive results from the AMPLIFY Phase III trial showed AstraZeneca's CALQUENCE® (acalabrutinib) in combination with venetoclax demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS)...



News published on and distributed by: